...
首页> 外文期刊>British Journal of Cancer >Inhibition by verapamil of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats
【24h】

Inhibition by verapamil of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats

机译:维拉帕米对N-亚硝基吗啉诱导的Sprague-Dawley大鼠肝癌发生的抑制作用

获取原文

摘要

The effect of verapamil on hepatocarcinogenesis induced by N-nitrosomorpholine (NNM) was investigated in male Sprague-Dawley rats. Rats were given drinking water containing NNM for 8 weeks and received i.p. injections of verapamil or vehicle every other day for 16 weeks from the start of the experiment. Pre-neoplastic and neoplastic lesions staining positive for gamma-glutamyl transpeptidase (GGT) or the placental type of glutathione-S-transferase (GST-P) were examined histochemically at week 16. Prolonged administration of verapamil resulted in a significant decrease in the number of GGT-positive and GST-P-positive lesions. The incidence and volume as a percentage of parenchyma of hepatocellular carcinomas were also significantly less in rats treated with verapamil than in controls. Administration of verapamil significantly decreased the labelling indices of pre-neoplastic lesions and adjacent liver. These findings indicate that verapamil inhibits hepatocarcinogenesis and that this may be related to its inhibitory effect on cell proliferation in neoplastic lesions and surrounding hepatocytes.
机译:在雄性Sprague-Dawley大鼠中研究了维拉帕米对N-亚硝基吗啉(NNM)诱导的肝癌发生的作用。大鼠接受含有NNM的饮用水8周,并接受腹膜内注射。从实验开始每隔16周注射一次维拉帕米或媒介。在第16周进行了组织化学检查,对γ-谷氨酰转肽酶(GGT)或胎盘型谷胱甘肽-S-转移酶(GST-P)染色呈阳性的肿瘤前和肿瘤病变进行了检查。长期服用维拉帕米会导致其数量显着减少GGT阳性和GST-P阳性的病变。用维拉帕米治疗的大鼠的肝细胞癌发病率和体积占实质的百分比也显着低于对照组。维拉帕米的使用显着降低了肿瘤前病变和邻近肝脏的标记指数。这些发现表明维拉帕米可抑制肝癌的发生,这可能与其对肿瘤性病变和周围肝细胞中细胞增殖的抑制作用有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号